肝素过敏患者颈动脉介入的替代抗凝:范围综述
该范围综述评估了颈动脉内膜切除术(CEA)或颈动脉支架置入术(CAS)中因肝素过敏使用非肝素抗凝的安全性。共纳入21项研究,涉及比伐卢定、阿加曲班和低分子肝素(LMWH)。比伐卢定在CAS中安全且出血少于普通肝素(UFH),阿加曲班和LMWH证据有限但可能可接受。
要点
- 比伐卢定用于颈动脉介入安全,围术期出血少于UFH。
- 阿加曲班仅小样本病例报告,未见不良事件。
- LMWH与UFH血栓和出血事件无显著差异,但栓塞风险更低。
核心结论
- 疑似UFH过敏需颈动脉介入的患者,比伐卢定是安全替代,阿加曲班和LMWH基于有限证据可接受。
- 比伐卢定围术期出血更少且不增加围术期并发症。
研究设计与样本
- PRISMA结构范围综述,检索PubMed、OVID Medline和OVID Embase 1993至2025年原始研究。
主要发现
- 比伐卢定文献包括3篇CEA病例报告、2项随机对照试验和6项CAS回顾性队列研究。
- 阿加曲班文献为5篇CEA病例报告和1篇CAS病例报告,均未报告不良事件。
- LMWH文献包括2项前瞻性随机对照试验、1项回顾性队列研究和1项病例系列,与UFH比较血栓和出血事件无显著差异,但LMWH栓塞风险更低。
临床怎么用
- 对疑似UFH过敏的颈动脉介入患者,可优先考虑比伐卢定作为替代抗凝。
- 阿加曲班和LMWH可作为备选,但需认识到证据有限。
局限性
- 纳入研究多为病例报告和回顾性研究,证据等级有限。
- 阿加曲班和LMWH相关证据尤其有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic unfractionated heparin (UFH) is routinely administered as procedural anticoagulation during carotid artery procedures. However, types I, II, and IV hypersensitivity to heparin can occur amongst patients with carotid artery disease who require carotid endarterectomy (CEA) or carotid artery stenting (CAS). Although rapid-acting nonheparin alternatives are available, their use for procedural anticoagulation in patients with suspected heparin hypersensitivity undergoing carotid intervention has not been thoroughly studied. We sought to evaluate the safety of nonheparin anticoagulant use in carotid artery interventions. METHODS: A PRISMA-structured scoping review was done to evaluate the outcomes of carotid interventions performed with nonheparin intraoperative anticoagulation. To do so, primary literature published between 1993 and 2025 was obtained using structured searches of PubMed, OVID Medline, and OVID Embase. Studies were included if they assessed major adverse cardiovascular events and excessive bleeding associated with nonheparin anticoagulation in CEA and CAS and were excluded if they did not have a primary focus on surgical outcomes or were not original research. Data on study characteristics, patient population, intervention, and clinical outcomes were extracted and summarized using a narrative synthesis to identify trends in the incidence and type of complication for a given alternative anticoagulant relative to UFH. RESULTS: A total of 90 deduplicated citations were identified, of which 21 met the criteria for inclusion. Eleven studies evaluated bivalirudin, six evaluated argatroban, and four evaluated low-molecular-weight heparin (LMWH). The bivalirudin literature included three case reports describing its use in CEA, as well as two randomized controlled trials and six retrospective cohort studies on its use in CAS. Bivalirudin was found to be safe for carotid procedures and was associated with less bleeding compared with UFH. Argatroban use was described in five case reports of CEA and one of CAS, none of which reported adverse events. Finally, two prospective randomized controlled trials, a retrospective cohort study, and a case series compared different LMWHs with UFH in CEA and found no significant difference in thrombotic or hemorrhagic events between the two treatment groups, but did note a lower risk of embolism with LMWH. CONCLUSIONS: In patients with suspected UFH hypersensitivity requiring carotid intervention, bivalirudin appears to be a safe alternative, while argatroban and LMWH may represent acceptable options based on limited available evidence. Bivalirudin, in particular, is associated with less perioperative bleeding and no increase in periprocedural complications.
引用
- Dmitriev AP, Akouris PP, Javidan AP, et al. Alternative anticoagulants in heparin-sensitive patients undergoing carotid artery interventions: A scoping review. J Vasc Surg. 2026. PMID: 41692040. doi:10.1016/j.jvs.2026.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。